Amwell (NYSE: AMWL) reported a significant improvement in its 2025 financial performance, sharply reducing its net loss to $95.0 million from $212.6 million in 2024. The company also enhanced its 2025 Adjusted EBITDA, improving it to $(39.9) million from $(134.4) million previously. However, Amwell issued cautious revenue guidance for 2026, forecasting figures between $195 million and $205 million. Conversely, the company projects continued improvement in 2026 Adjusted EBITDA, expecting it to reach a range of $(24) million to $(18) million. Amwell aims to achieve positive cash flow from operations by the fourth quarter of 2026, driven by its strategic shift towards a leaner, more efficient model.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis